0001104659-25-032208.txt : 20250404 0001104659-25-032208.hdr.sgml : 20250404 20250404161001 ACCESSION NUMBER: 0001104659-25-032208 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250402 FILED AS OF DATE: 20250404 DATE AS OF CHANGE: 20250404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ferguson Toby CENTRAL INDEX KEY: 0002015616 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37625 FILM NUMBER: 25814654 MAIL ADDRESS: STREET 1: VOYAGER THERAPEUTICS, INC. STREET 2: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Voyager Therapeutics, Inc. CENTRAL INDEX KEY: 0001640266 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-259-5340 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 tm2511532-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2025-04-02 0 0001640266 Voyager Therapeutics, Inc. VYGR 0002015616 Ferguson Toby C/O VOYAGER THERAPEUTICS, INC. 75 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Medical Officer 0 Common Stock 2025-04-02 4 S 0 10086 3.43 D 157914 D Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2025. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.51, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. /s/ Scott MacDonald, as Attorney-in-Fact for Toby Ferguson 2025-04-04